A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Trial ID or NCT#

NCT05168202

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodysplastic syndromes.

Official Title

A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Gabriel Mannis
Gabriel Mannis
Hematologist-Oncologist
Associate Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

Ji Hyun Choi
+1 650-723-1367

View on ClinicalTrials.gov